BLACK DIAMOND THERAPEUTICS INC. - COMMON STOCK

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

06 Mar 2025 16:01:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

05 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

01 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

07 Oct 2024 16:01:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

23 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

22 Sep 2024 10:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

14 Sep 2024 03:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

06 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

01 Jun 2024 10:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

29 May 2024 08:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Changes to Board of Directors

11 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

07 Apr 2024 18:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

03 Apr 2024 08:00:01 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

12 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

05 Mar 2024 16:30:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

28 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

13 Dec 2023 07:00:00 By Nasdaq GlobeNewswire